The interaction between GRB7 and PLK1 reactivates the MAPK pathway, suggesting that a combination therapy involving PLK1 and MEK inhibitors could be efficacious in overcoming this resistance, thereby presenting a new avenue for treating KRAS-mutated colon cancer.479 Zhou et al. demonstrated that variations in the expression of histone modification factors correlate with drug resistance in tumor cells, highlighting the heterogeneity among patients. The gene discussed is KRAS; the disease is neoplasm.